Cycle 8 Cycle 10 Cycle 8 Cycle 10 Responding New lesions Figure 1 | Clinical response of index patient treated with BYL719. CT scans showing stable (responding) peri-aortic lymph node metastasis (yellow circles, left column) and the appearance of new lung metastatic lesions (yellow circles, right column) after the completion of the tenth cycle of BYL719 therapy. Arrow, pleural effusion.
Broad and deep tumour genome sequencing has shed new light on tumour heterogeneity and provided important insights into the evolution of metastases arising from different clones 1, 2 . There is an additional layer of complexity, in that tumour evolution may be influenced by selective pressure provided by therapy, in a similar fashion to that occurring in infectious diseases. Here we studied tumour genomic evolution in a patient (index patient) with metastatic breast cancer bearing an activating PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PI(3)Ka) mutation. The patient was treated with the PI(3)Ka inhibitor BYL719, which achieved a lasting clinical response, but the patient eventually became resistant to this drug (emergence of lung metastases) and died shortly thereafter. A rapid autopsy was performed and material from a total of 14 metastatic sites was collected and sequenced. All metastatic lesions, when compared to the pre-treatment tumour, had a copy loss of PTEN (phosphatase and tensin homolog) and those lesions that became refractory to BYL719 had additional and different PTEN genetic alterations, resulting in the loss of PTEN expression. To put these results in context, we examined six other patients also treated with BYL719. Acquired bi-allelic loss of PTEN was found in one of these patients, whereas in two others PIK3CA mutations present in the primary tumour were no longer detected at the time of progression. To characterize our findings functionally, we examined the effects of PTEN knockdown in several preclinical models (both in cell lines intrinsically sensitive to BYL719 and in PTEN-null xenografts derived from our index patient), which we found resulted in resistance to BYL719, whereas simultaneous PI(3)K p110b blockade reverted this resistance phenotype. We conclude that parallel genetic evolution of separate metastatic sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Ka inhibition.
We are currently engaged in testing the antitumour activity of a novel PI(3)Ka inhibitor, BYL719, in patients with tumours harbouring activating PI(3)Ka mutations 3 . The PI(3)K pathway is essential for cell growth, proliferation, survival, and metabolism 4, 5 . The PI(3)K family of enzymes is divided into three main classes (I to III), with class I being the most often implicated in human cancer 6 . Class IA PI(3)K is a heterodimer composed of a catalytic subunit (p110a, b or d) and a regulatory subunit 7, 8 . PIK3CA, the gene encoding p110a, is mutated in up to 40% of oestrogen receptor (ER) and/or HER2 positive breast tumours 9, 10 . In our ongoing phase I clinical study of BYL719, we have observed clinical responses in breast, head and neck and other tumours 3 , providing proof of principle that PI(3)Ka targeting is active against tumours harbouring PIK3CA mutation.
We present the case of a 60-year-old breast cancer patient (index patient) diagnosed with invasive ductal carcinoma who underwent surgery followed by adjuvant treatment with chemotherapy and the aromatase inhibitor examestane. Four years later, the patient developed bone metastases and started therapy with the ER antagonist fulvestrant, achieving stable disease. After 18 months on therapy, her disease progressed in the liver, bone and lymph nodes. The archival tissue of the primary tumour was subjected to PCR-based genetic analysis 11 and a hot spot mutation in PIK3CA (E542K) was detected. This finding led to the patient's enrolment in a phase I clinical trial testing the tolerability and antitumour activity of BYL719 (NCT01219699). The patient rapidly achieved a confirmed partial response according to the RECIST 1.0 criteria 12 that lasted 9.5 months ( Table 1 and Extended Data Fig. 1 ). At that point, while the tumour remained stable in multiple sites including a peri-aortic lymph node location, progression occurred in the lungs ( Fig. 1 ) and consequently 
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therapy with BYL719 was discontinued. The clinical status of the patient deteriorated rapidly and she died two months after termination of the BYL719 treatment. A rapid autopsy was performed three hours after death and a total of 14 metastases with tumour cells present were identified and collected for sequencing (Extended Data Table 1 ).
In order to proceed systematically to identify possible genetic determinants of acquired resistance to PI(3)Ka inhibition, we took a threestep approach. First, we examined both the primary tumour (before BYL719 treatment) and the new lung metastasis by whole genome sequencing (WGS). Although both samples shared many somatic genetic aberrations ( Fig. 2a and Extended Data Fig. 2 ), PTEN copy number loss was detected only in the lung metastasis ( Fig. 2b) . Second, we analysed by whole exome sequencing (WES) the primary tumour, lung metastasis, and the peri-aortic lesion that remained stable (responding) at the time of progression to BYL719 therapy (Fig. 2c ). This analysis revealed that both peri-aortic and lung lesions harboured mutations in PIK3CA, ESR1 and BRCA2, and single copy loss of PTEN. Importantly, in addition to the PTEN copy number loss, we identified a PTEN del339FS (frameshift) mutation only in the lung metastasis ( Fig. 2c ). By immunohistochemistry (IHC), we observed that PTEN protein expression was lost in the lung metastasis but was present in both the primary tumour and peri-aortic lesion (Fig. 2d ).
Third, to confirm and expand our findings, we sequenced the primary tumour and all the metastatic lesions to .500-fold coverage using a custom targeted deep-sequencing assay, IMPACT 13, 14 (Methods). A number of mutations were shared by the primary tumour and the metastatic sites, whereas others were observed only in all or in selected metastatic lesions ( Fig. 3a and Supplementary Table) . We confirmed that the PIK3CA E542K mutation in the primary tumour was conserved in the metastatic samples and detected the presence of another PIK3CA mutation (D725G). Moreover, we found increased copy number of FGFR1 and EI4EBP1 in all tumour samples, consistent with the relatively frequent 8p11-12 amplification described in breast cancer 15, 16 . ESR1 Y537N and BRCA2 L971S alterations were present in all the metastatic lesions but not in the primary tumour. We speculate that the ESR1 Y537N mutation, reported to promote ligand-independent ER activation 13 , was selected upon anti-oestrogen therapy received by the patient before BYL719 treatment.
Central to our work, all metastatic lesions appeared to harbour a single copy loss of PTEN (Extended Data Fig. 3 ). Furthermore, we found that 10 of the 14 metastatic lesions harboured additional genomic alterations within PTEN. The spectrum of PTEN alterations was heterogeneous across the 10 samples and included a splice site mutation at K342, a frameshift indel at P339 (confirming the WES result), and 4 different exon-level deletions ( Fig. 3a and Extended Data Fig. 4 ). All 10 specimens with either secondary PTEN mutations or copy number loss were confirmed negative for PTEN staining by IHC, whereas the four specimens that retained a PTEN wild-type allele were positive for PTEN protein expression (Extended Data Fig. 5 ). In addition, for those lesions 
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that were visualized by CT (computerized tomography) scan, there was a tight correlation between progression of disease and loss of PTEN expression. The peri-aortic lesion (M02) that was responding at the time of disease progression still contained one PTEN wild-type allele and protein expression. Conversely, the lung lesions (M04, M06, M09 and M11) and liver lesion (M12) with documented progression to therapy had bi-allelic PTEN alteration and lack of expression. In an effort to integrate the genomic data from our patient, we constructed a dendrogram mapping the phylogenetic evolution of the disease. Our findings suggest that all the lesions were derived from the PTEN wild-type primary tumour, and that there was a progressive and parallel loss of PTEN under BYL719 selective pressure (Fig. 3b ). Of note, the two-month duration between progression to BYL719 and autopsy needs to be considered as well.
In order to expand our observations, we analysed paired samples (pretreatment and at progression) from six additional patients enrolled in the same study at our institution ( Table 1 ). Targeted sequencing identified homozygous loss of PTEN in a post-treatment sample of a breast cancer patient who developed resistance to BYL719 after initially experiencing a durable response to therapy ( Table 1 ). We also confirmed lack of PTEN expression by IHC in the post-treatment sample (Extended Data Fig. 6 ). We found no detectable PIK3CA mutations in the posttreatment samples of two patients ( Table 1) . Given that the presence of PIK3CA mutations drove sensitivity to BYL719 in our cell line screens 17 , positive selection of clones bearing wild-type alleles of PIK3CA may explain the emergence of resistance to BYL719 in these two additional cases. These results may be an indication that in some cases PIK3CA mutations are not early founder/truncal events but branched subclonal drivers that are cleared from the tumours under the selective pressure of PI(3)Ka inhibition. In any case, the fact that loss of PTEN expression and emergence of PIK3CA wild-type clones are mutually exclusive in our patient samples indicates that both events may be important in opposing the therapeutic efficacy of BYL719.
No other alterations with an obvious connection to BYL719 resistance were found in the responding cases, with the exception of a mutation (E1490*) and an in-frame deletion in MAP3K1 in one of the three patients for whom neither PTEN nor PIK3CA status changed during BYL719 treatment. Further characterization is needed to determine whether these mutations lead to increased MEK and ERK signalling and limit the effects of PI(3)K inhibition.
PTEN encodes for a phosphatase that regulates the activity of PI(3)K by limiting the accumulation of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 or PIP 3 ), a required mediator to initiate the PI(3)K/ AKT/mTOR signalling cascade 18 . In the absence of PTEN, cancer cells become dependent mostly on the activity of the p110b isoform of PI LETTER RESEARCH effectors 19, 20 . Therefore, we hypothesized that progressive decrease or loss of PTEN expression in the presence of PI(3)Ka inhibition might restore PI(3)K/AKT signalling through PI(3)Kb activity. To test our hypothesis, we established cell lines expressing either doxycyclineinducible or constitutive short hairpin (sh)RNA against PTEN messenger RNA using T47D and MCF7 cells, known to be intrinsically sensitive to BYL719 21 . As expected, induction of PTEN downregulation led to activation of AKT and the downstream effectors PRAS40, GSK3b and S6 in both T47D (Fig. 4a ) and MCF7 (data not shown) cells under basal conditions. PTEN downregulation markedly limited the effects of BYL719, both at the signalling and cell viability level. On the other hand, PTEN knockdown did not result in resistance to the pan-PI(3)K inhibitor BKM120, which blocks all the PI(3)K p110 isoforms ( Fig. 4b and Extended Data Fig. 7a) . Similar effects were observed in another BYL719sensitive cell line (MDA-MB-453) with constitutive PTEN knockdown (Extended Data Fig. 7b ).
From our patient's non-responding PTEN-null lung metastatic lesion, we were able to establish xenografts in nude mice. Consistent with the in vitro data, this patient-derived xenograft (PDX) was resistant to BYL719 treatment but sensitive to BKM120 (Fig. 4c ). The degree of inhibition of phospho-AKT and phospho-S6 was also higher with BKM120 ( Fig. 4d and Extended Data Fig. 7c and d) . These results were complemented by the combination of BYL719 and the PI(3)Kb inhibitor AZD6482. Upon PTEN knockdown, only combined PI(3)Ka and b blockade was capable of reverting the resistant phenotype ( Fig. 4e and Extended Data Fig. 8a) . Similarly, the BYL719-resistant PDX was insensitive to AZD6482 alone but responded to the combination of both compounds (Fig. 4f ). Profound inhibition of AKT and S6 phosphorylation was achieved only upon treatment with BYL719 in combination with AZD6482 ( Fig. 4g and Extended Data Fig. 8b and c) . Taken together, these data indicate that inhibition of the PI(3)Kb isoform is required to achieve antitumour activity in cells/tumours that lost PTEN expression and become resistant to BYL719.
We have reported a case of parallel genetic evolution under selective therapeutic pressure leading to a progressive loss of PTEN expression and consequent gain of dependency on the PI(3)Kb isoform. Parallel evolution under selective pressure has been described in conditions where treatments are highly efficacious, such as in HIV 22 . Our case highlights that this tumour, despite its heterogeneity, was dependent on PI(3)K signalling, probably as a result of the presence of the same activating PIK3CA mutation in all the tumour sites. Upon continued suppression of PI(3)Ka, diverse genomic alterations emerged, leading to PTEN loss as an alternative mechanism of PI(3)K activation. Moreover, our study emphasizes the importance of tumour interrogation upon progression to therapy and the dynamic nature of tumour genomes under selective therapeutic pressure.
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